Results 1 to 10 of about 8,597,475 (170)

Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy [PDF]

Pharmaceuticals
Purpose: The aim was to compare the short-term outcomes of aflibercept 8 mg and brolucizumab for the treatment of polypoidal choroidal vasculopathy (PCV). Methods: This study included 48 eyes of 48 patients with PCV.
Yoshiko Fukuda, Yoichi Sakurada, Yumi Kotoda, Misa Kimura, Kenji Kashiwagi   +4 more
doaj   +5 more sources

Advances in Polypoidal Choroidal Vasculopathy (PCV) Management: Emerging Evidence for Faricimab and Aflibercept 8 mg [PDF]

Ophthalmology and Therapy
Introduction Polypoidal choroidal vasculopathy (PCV) is a major subtype of neovascular age-related macular degeneration (nAMD), particularly prevalent in Asian and pigmented populations.
Mohamed Zakaria Sherif, Kelvin Y. C. Teo, Timothy Y. Y. Lai, Hiok Hong Chan, Beau J. Fenner, Won Ki Lee, Chui Ming Gemmy Cheung   +6 more
doaj   +4 more sources

Bilateral Sterile Intraocular Inflammation Following Intravitreal Aflibercept 8 mg Injections: A Case Report [PDF]

Reports
Background and Clinical Significance: To report a case of bilateral sterile intraocular inflammation following intravitreal aflibercept 8 mg (Eylea HD) injections.
Ram Cohen, Tomer Kerman, Omer Trivizki
doaj   +5 more sources

Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial. [PDF]

JAMA Ophthalmol
Importance In the Study of the Effects of High-Dose Aflibercept Injected Into the Eye of Patients With an Age-Related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR) phase 3 randomized clinical trial, treatment with aflibercept, 8 mg, demonstrated ...
Lee WK, Wong TY, Chen SJ, Sun X, Cheung CMG, Silva R, Ricci F, Zhang X, Machewitz T, Schulze A, Schmidt-Ott UM, Zhao M, Hasanbasic Z, Leal S, Iida T, PULSAR Study Investigators.   +15 more
europepmc   +5 more sources

Intraocular inflammation following aflibercept 8 mg: real-world data from a multicentre retrospective observational study [PDF]

International Journal of Retina and Vitreous
Background Real-world data on intraocular inflammation (IOI) following aflibercept 8 mg is limited. We report on a cluster of 12 eyes with aflibercept 8 mg-associated IOI detected at three centres between July 2024 and June 2025.
Lea-Noelle Stoehr, Philip Wakili, Warda Darwisch, Franziska Seufert, Robert P. Finger, Peter Szurman, Boris V. Stanzel   +6 more
doaj   +4 more sources

Non-infectious occlusive retinal vasculitis following switching from aflibercept 2 mg to aflibercept 8 mg in neovascular age-related macular degeneration: a case report [PDF]

BMC Ophthalmology
Background Anti–vascular endothelial growth factor (anti-VEGF) therapy represents the standard of care for neovascular age-related macular degeneration (nAMD).
Ermal Simaku, Ahmed Nour Eddien, Megi Popa, Ahmed El Shafei   +3 more
doaj   +3 more sources

Short-Term Intraocular Pressure Changes After Intravitreal Aflibercept 8 mg via Prefilled Syringe [PDF]

Ophthalmology and Therapy
Introduction Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is a standard treatment for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO).
Arianna Peyla, Matteo Bonanata, Martina Pache, Michele Clerici, Moreno Menghini, Gabriela Grimaldi, Giulio Volpe   +6 more
doaj   +2 more sources

Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON [PDF]

Ophthalmology and Therapy
Introduction This abstract aimed to explore the potential effect of a higher injection volume with aflibercept 8 mg (70 μl) versus 2 mg (50 μl) on intraocular pressure (IOP).
Anat Loewenstein, Ursula Schmidt-Ott, Diana V. Do, Paolo Lanzetta, Sergio Leal, Alyson J. Berliner, Karen W. Chu, Mark R. Barakat, Ghassan Ghorayeb, Michael W. Stewart, Martin S. Spitzer, Xin Zhang, April McCullough, Claudia Tueckmantel, Dianela Avila, Peter Morgan-Warren, Lynne Brunck, Ajla Dupljak, Maggie Hymowitz, Anna Portnoy, Richard Gale   +20 more
doaj   +2 more sources

Two-dose aflibercept 8 mg versus three-dose aflibercept 2 mg loading for treatment-naïve neovascular age-related macular degeneration. [PDF]

PLoS ONE
This retrospective study compared the short-term efficacy of a two-dose intravitreal aflibercept (IVA) 8-mg loading regimen (2024-2025) with a conventional three-dose IVA 2-mg regimen (2013-2014) for treatment-naïve neovascular age-related macular ...
Mai Shirakami, Manabu Miyata, Masayuki Hata, Sotaro Ooto, Hiroshi Tamura, Ai Otsuka, Lin Tsukui, Naoko Ueda-Arakawa, Masahiro Miyake, Ayako Takahashi, Shin Kadomoto, Yuki Muraoka, Akitaka Tsujikawa   +12 more
doaj   +2 more sources

Peripapillary Retinal Nerve Fibre and Ganglion Cell Layer Changes Following Intravitreal Aflibercept 8 mg Therapy in Neovascular Age-Related Macular Degeneration: A Longitudinal OCT Study [PDF]

Ophthalmology and Therapy
Introduction Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard of care for neovascular age-related macular degeneration (nAMD) and other retinal vascular diseases.
Giulio Volpe, Matteo Bonanata, Arianna Peyla, Ludovico Ruscitti, Veronika Eggarter, Martina Pache, Arianna Paris, Moreno Menghini, Gabriela Grimaldi   +8 more
doaj   +2 more sources